Skip to content
Triangle logo TriangleGet started
← Study library

NCT04843579 · REGISTRY CONDITION SEARCH

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2023-10-25

The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple myeloma. The hypothesis is that the addition of Selinexor to Clarithromycin, Pomalidomide and Dexamethasone will increase the overall response rate of patients with relapsed/refractory multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Percentage of Participants With Overall Response Rate of Partial Response or Better

→

outcome · POSTED

Number of Participants With Adverse Events

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Written informed consent in accordance with federal, local, and institutional guidelines. * Age ≥18 and \<75 years at the time of informed consent. * Confirmed diagnosis of multiple myeloma * Symptomatic multiple myeloma per IMWG guidelines. * Measurable disease as defined by at least one of the following: a. Serum M-protein ≥ 0.5 g/dL by serum protein electrophoresis (SPEP) or, for IgA myeloma, by quantitative IgA, and/or b. Urinary M-protein excretion at least 200 mg/24 hours, and/or c. Serum FLC ≥ 100 mg/L, provided that FLC ratio is abnormal, and/or d. If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement (e.g., for IgA MM), then quantitative Ig levels by nephelometry or turbidimetry are acceptable. * Relapsed and refractory multiple myeloma with documented evidence of PD after achieving at least SD for ≥ 1 cycle during a previous MM regimen (i.e., relapsed MM), and ≤ 25% response (i.e., patients never achieved ≥ MR) or PD during or within 60 days from the end of the most recent MM regimen (i.e., refractory MM). * Previously received one to four prior lines of therapy and be pomalidomide-naïve. Exclusion Criteria: * Documented active systemic light chain amyloidosis. * Active plasma cell leukemia. * Eastern Cooperative Oncology Group (ECOG) Performance Status greater than 2. * Persistent non-hematological toxicity (except for peripheral neuropathy) from a prior treatment which has not resolved to at least Grade 2 or better by Cycle 1 Day 1 (C1D1). * Severe hepatic dysfunction with either: a. Total bilirubin \> 2x ULN (\> 3x ULN in subjects with Gilbert's syndrome \[hereditary indirect hyperbilirubinemia\]), and/or b. AST and/or ALT \> 2.5x ULN * Severe renal dysfunction with an estimated creatinine clearance of \< 15 mL/min calculated using the Cockcroft and Gault formula. * Impaired hematopoietic function with either: a. White blood cell count \< 1,500/mm3, and/or b. Absolute neutrophil count \< 1000/mm3, and/or c. Hemoglobin \< 8.0 g/dL, and/or d. Platelet count \< 100,000/mm3 (for patients in whom ≥ 50% of bone marrow nucleated cells are plasma cells, platelets ≥ 75,000/mm3 are acceptable). * Blood (or blood product) transfusions or blood growth factors within 7 days of C1D1. Use of hematopoietic growth factor support is acceptable, including erythropoietin (EPO), darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), and platelet stimulators (e.g., eltrombopag or romiplostim). However, patients must be platelet transfusion independent for \> 1 week in order to be enrolled in the study. * Radiation, chemotherapy or immunotherapy, or any other anticancer therapy within 2 weeks prior to C1D1, or radio-immunotherapy within 6 weeks prior to C1D1. Patients on long-term glucocorticoids during Screening do not require a washout period. Prior radiation is permitted for treatment of fractures or to prevent fractures, as well as for pain management. * Patients with history of spinal cord compression with residual paraplegia. * Treatment with an investigational anti-cancer therapy within 3 weeks prior to C1D1. * Prior autologous stem cell transplantation \< 1 month, or allogeneic stem cell transplantation \< 3 months prior to C1D1. * Active graft versus host disease after allogeneic stem cell transplantation. * Life expectancy \< 3 months. * Major surgery within 4 weeks prior to C1D1. * Active, unstable cardiovascular function with either: a. Symptomatic ischemia, b. Uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded), c. Congestive heart failure (CHF) of New York Heart Association (NYHA) Class ≥ 3, d. Myocardial infarction (MI) within 6 months prior to C1D1, or e. Screening 12-lead ECG showing a baseline QT interval as corrected by Bazett's formula (QTc) \> 470 msec * Uncontrolled active hypertension * Venous thromboembolism within 6 months prior to C1D1 or a known inherited thrombophilia * Inability to receive either prophylactic or therapeutic anticoagulation as determined appropriate by the Investigator * Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to C1D1 * Any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment * Currently pregnant or breastfeeding. Lactating females must agree not to breast feed while receiving selinexor, pomalidomide and/or clarithromycin * A serious psychiatric or medical condition which, in the opinion of the Investigator, could interfere with treatment * Hypersensitivity or contraindication to selinexor, pomalidomide, dexamethasone and/or clarithromycin * Prior exposure to a SINE compound, including selinexor * Concomitant use of any strong CYP3A4 and/or CYP1A2 inhibitors (see Appendix 1) * Unable to obtain commercial clarithromycin, pomalidomide and dexamethasone through a regular and/or specialty pharmacy. * Unable or unwilling to register into the mandatory POMALYST REMSTM program and comply with its requirements. * Male and female patients unwilling or unable to use effective methods of contraception throughout the study and for three months following the last dose. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. Note that female patients of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at Screening and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential.
healthy Volunteers
false
maximum Age
74 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Selinexor • Given orally at a dose of 60 mg on days 1, 8, and 15 of a 28-day cycle. Dexamethasone * Given orally at a dose of 40 mg on days 1, 8, 15 and 22 of a 28-day cycle. * Subjects will receive a prescription for dexamethasone 4 mg tablets (generic). Clarithromycin * Given orally at a dose of 500 mg twice a day on days 1-28 of a 28-day cycle. * Subjects will receive a prescription for clarithromycin 250 or 500 mg tablets (generic) for oral administration. Pomalidomide * Given orally at a dose of 4 mg daily on days 1-21 of a 28-day cycle. * Subjects will receive a 21-day supply of pomalidomide 1, 2, 3, or 4 mg capsules for oral administration for each treatment cycle.
    intervention Names
    1. Drug: Selinexor
    2. Drug: Clarithromycin
    3. Drug: Pomalidomide
    4. Drug: Dexamethasone
    label
    Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)
    description
    Given as 60 mg oral capsule
    name
    Selinexor
    type
    DRUG
  2. arm Group Labels
    1. Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)
    description
    Given as 500 mg oral capsule
    name
    Clarithromycin
    type
    DRUG
  3. arm Group Labels
    1. Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)
    description
    Given as 4 mg oral capsule
    name
    Pomalidomide
    type
    DRUG
  4. arm Group Labels
    1. Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)
    description
    Given as 40 mg oral capsule
    name
    Dexamethasone
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
4
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    ORR is defined as participants who experience a partial response, very good partial response, complete response, or stringent complete response per International Myeloma Working Group Criteria (IMWG) 2016 criteria. Complete Response is defined as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates. Stringent Complete Response is defined as complete response as noted previously plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immune-histochemistry. Partial Response is ≥50% reduction of serum M-protein plus reduction in 24 hour urinary M-protein by ≥90% or to \<200 mg per 24 h. Very Good Partial Response is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hr.
    measure
    Percentage of Participants With Overall Response Rate of Partial Response or Better
    time Frame
    Until disease progression; the maximum time any participant was followed for ORR was 287 days
secondary Outcomes
  1. description
    Adverse events will be determined by Events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The frequency of adverse events will be collected in tabular summary from when a participant consent to study until end of study or patient participant starts a new treatment.
    measure
    Number of Participants With Adverse Events
    time Frame
    Adverse events were collected from time of informed consent until 30 days after the last day of study drug administration for each participant. The maximum period that AEs were collected for a participant was 300 days.
Full study description
brief Summary
The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple myeloma. The hypothesis is that the addition of Selinexor to Clarithromycin, Pomalidomide and Dexamethasone will increase the overall response rate of patients with relapsed/refractory multiple myeloma.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-5b0126e9d36d93a110f9
      requested nct id
      NCT04843579
      primary nct id
      NCT04843579
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      2ee8bd8f0328f5270884bec40d2262403cafec024b43dac50332ad42af175fd5
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-5b0126e9d36d93a110f9
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT04843579
      occurrences
      1. context exact
        NCT04843579
        end
        11
        exact text
        NCT04843579
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/794/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      311d99ab860159828c7bf77260634c0b884c0398984fd75d018d4fde85f59d93

    Preserved source evidence · Not medical advice